FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION

1 . A pharmaceutical formulation comprising iclaprim or an enantiomer thereof and a sulfonamide antibiotic.

2 . The formulation of claim 1 , wherein the sulfonamide antibiotic is selected from the group consisting of sulfisoxazole, sulfadimethoxine, sulfamethoxazole, 4-sulfanilamido-5,6-dimethoxy-pyrimidine (sulfadoxine), 2-sulfanilamido-4,5-dimethyl-pyrimidine, sulfaquinoxaline, sulfadiazine, sulfamonomethoxine, and 2-sulfanilamido-4,5-dimethyl-isoxazole or dapsone.

3 . The formulation of claim 1 , wherein the sulfonamide antibiotic is sulfamethoxazole.

4 . The formulation of claim 1 , wherein the iclaprim or an enantiomer thereof and sulfonamide antibiotic are present in a ratio of from about 1:0.1 to 1:4.5 of iclaprim or an enantiomer thereof to sulfonamide antibiotic.

5 . The formulation of claim 1 , wherein the iclaprim or an enantiomer thereof and sulfonamide antibiotic are present in a ratio of from about 1:1, 1:2 or 1:3 of iclaprim or an enantiomer thereof to sulfonamide antibiotic.

6 . The formulation of claim 1 , wherein the iclaprim or an enantiomer thereof and sulfonamide antibiotic are present in a ratio of from about 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4 and 1:4.5 of iclaprim or an enantiomer thereof to sulfonamide antibiotic.

7 . The formulation of claim 1 , which is formulated for intravascular administration.

8 . The formulation of claim 7 , wherein the intravascular administration is intravenous.

9 . The formulation of claim 1 , which is formulated for oral administration.

10 . The formulation of claim 9 , wherein the formulation comprises a tablet, caplet or capsule.

11 . The formulation of claim 10 , wherein the tablet further comprises a surfactant, a lubricant, a disintegrant, a diluent or a binder.

12 . The formulation of claim 10 , wherein the tablet further comprises docusate sodium, sodium benzoate, sodium starch glycolate, magnesium stearate and pregelatinized starch.

13 . The formulation of claim 1 , comprising about 160 mg of iclaprim or an enantiomer thereof and about 160 to 480 mg of sulfonamide antibiotic.

14 . The formulation of claim 1 , comprising about 160 mg of iclaprim or an enantiomer thereof and about 160 mg of sulfonamide antibiotic; about 160 mg of iclaprim or an enantiomer thereof and about 320 mg of sulfonamide antibiotic; or about 160 mg of iclaprim or an enantiomer thereof and about 480 mg of sulfonamide antibiotic.

15 . The formulation of claim 1 , wherein the iclaprim or an enantiomer thereof is substantially the R-enantiomer of iclaprim.

16 . A method of treating a bacterial or fungal infection in a subject, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation comprising iclaprim or an enantiomer thereof and a sulfonamide antibiotic.

17 . The method of claim 16 , wherein the sulfonamide antibiotic is selected from the group consisting of sulfisoxazole, sulfadimethoxine, sulfamethoxazole, 4-sulfanilamido-5,6-dimethoxy-pyrimidine (sulfadoxine), 2-sulfanilamido-4,5-dimethyl-pyrimidine, sulfaquinoxaline, sulfadiazine, sulfamonomethoxine, and 2-sulfanilamido-4,5-dimethyl-isoxazole or dapsone.

18 . The method of claim 16 , wherein the sulfonamide antibiotic is sulfamethoxazole.

19 . The method of claim 16 , wherein the iclaprim or an enantiomer thereof and sulfonamide antibiotic are present in the pharmaceutical formulation in a ratio of from about 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4 and 1:4.5 of iclaprim or an enantiomer thereof to sulfonamide antibiotic.

20 . The method of claim 16 , wherein the bacterial or fungal infection comprises infection with Streptococcus pneumoniae; Escherichia coli; Haemophilus influenzae; Morganella morganii; Proteus mirabilis; Proteus vulgaris; Shigella flexneri; Shigella sonnei; Pneumocystis jiroveci ; or methicillin-resistant Staphylococcus aureus.